Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has announced that it has observed positive results from its Phase 2 clinical study of its drug anabasum that is aimed at treating dermatomyositis.
The biopharma was pleased to announce the positive results of the anabasum clinical trial results. Corbus has been developing the drug for treating dermatomyositis, a rare inflammatory condition that is characterized by progressive muscle weakness as well as a painful and itchy rash, and is over 50% fatal at 10 years post diagnosis. There were 22 adults participating in the clinical trials which spanned a duration of 16 weeks. The pharmaceutical company revealed that the primary efficacy outcome of the drug performed better than placebo in both the primary and secondary efficacy outcomes.
“These trial results mark the third time anabasum has demonstrated a clear signal of clinical benefit with a favorable safety profile in a rare, inflammatory disease, having done so recently in both systemic sclerosis and cystic fibrosis,” stated Corbus CEO Yuval Cohen.
The results of the study indicated significant progress in skin affected by the disease in each patient and it also scored quite high compared to the placebo group. The biopharma also revealed that the patients involved in the clinical trials tolerated the treatment quite well and that there were no serious side effects reported.
Cohen also pointed out that the data from the study is a strong validator of the mechanism of in which the drug was engineered to work. He also added that anabasum is slated to be the first non-immunosuppressive treatment of its kind to address fibrosis and inflammation. The biopharma now plans to divert its focus towards running a clinical development plan that will facilitate the introduction of Anabasum to the market as fast as possible.
Meanwhile, the announcement of the positive results of the clinical trials for the Anabasum treatment led to a surge in Corbus’ stock thus indicating that investors were happy with the results. The stock experienced a 21.4 percent surge before the markets opened on Thursday, but has settled down somewhat since then.
Corbus stock closed the latest trading session on Thursday at $7.70 after a 10 percent gain compared to the value of the stock during the previous close.
